BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26522726)

  • 21. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GSK3-mediated raptor phosphorylation supports amino-acid-dependent mTORC1-directed signalling.
    Stretton C; Hoffmann TM; Munson MJ; Prescott A; Taylor PM; Ganley IG; Hundal HS
    Biochem J; 2015 Sep; 470(2):207-21. PubMed ID: 26348909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
    Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
    Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.
    Coffey RT; Shi Y; Long MJ; Marr MT; Hedstrom L
    J Biol Chem; 2016 Mar; 291(10):5221-33. PubMed ID: 26740621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1).
    Fonseca BD; Zakaria C; Jia JJ; Graber TE; Svitkin Y; Tahmasebi S; Healy D; Hoang HD; Jensen JM; Diao IT; Lussier A; Dajadian C; Padmanabhan N; Wang W; Matta-Camacho E; Hearnden J; Smith EM; Tsukumo Y; Yanagiya A; Morita M; Petroulakis E; González JL; Hernández G; Alain T; Damgaard CK
    J Biol Chem; 2015 Jun; 290(26):15996-6020. PubMed ID: 25940091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension.
    Aghamohammadzadeh R; Zhang YY; Stephens TE; Arons E; Zaman P; Polach KJ; Matar M; Yung LM; Yu PB; Bowman FP; Opotowsky AR; Waxman AB; Loscalzo J; Leopold JA; Maron BA
    FASEB J; 2016 Jul; 30(7):2511-27. PubMed ID: 27006450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.
    Becker MA; Ibrahim YH; Cui X; Lee AV; Yee D
    Mol Endocrinol; 2011 Mar; 25(3):516-28. PubMed ID: 21292829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression.
    Ekim B; Magnuson B; Acosta-Jaquez HA; Keller JA; Feener EP; Fingar DC
    Mol Cell Biol; 2011 Jul; 31(14):2787-801. PubMed ID: 21576368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
    Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
    Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of amino acid transporter trafficking by mTORC1 in primary human trophoblast cells is mediated by the ubiquitin ligase Nedd4-2.
    Rosario FJ; Dimasuay KG; Kanai Y; Powell TL; Jansson T
    Clin Sci (Lond); 2016 Apr; 130(7):499-512. PubMed ID: 26608079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.
    Bratton MR; Martin EC; Elliott S; Rhodes LV; Collins-Burow BM; McLachlan JA; Wiese TE; Boue SM; Burow ME
    J Steroid Biochem Mol Biol; 2015 Jun; 150():17-23. PubMed ID: 25771071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
    Citro S; Miccolo C; Meloni L; Chiocca S
    J Mol Cell Biol; 2015 Apr; 7(2):132-42. PubMed ID: 25801958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
    Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
    Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f).
    Cuesta R; Berman AY; Alayev A; Holz MK
    J Biol Chem; 2019 Feb; 294(7):2267-2278. PubMed ID: 30573685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.
    Andruska N; Zheng X; Yang X; Helferich WG; Shapiro DJ
    Oncogene; 2015 Jul; 34(29):3760-9. PubMed ID: 25263449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.